ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • CorCMR: Stress CMR Imaging May Help Improve Diagnosis and Treatment of Angina
    Stress cardiac magnetic resonance (CMR)-guided management of patients with chest pain and nonobstructive coronary artery disease was superior to angiography-guided management alone in correctly diagnosing microvascular angina and improving chest pain symptoms and quality of life after six months to one year...
  • TUXEDO-2: Ticagrelor vs. Prasugrel in Patients With Diabetes and Multivessel Disease After PCI
    In patients with diabetes and multivessel coronary artery disease undergoing PCI, a ticagrelor-based dual antiplatelet therapy (DAPT) regimen did not offer the same level of benefit at preventing heart attack, stroke, bleeding complications or death as a prasugrel-based DAPT regimen...
  • CELEBRATE: Zalunfiban vs. Placebo at First Medical Contact in Patients With STEMI?
    A single subcutaneous injection of zalunfiban administered on first medical contact with patients with suspected STEMI was associated with improved patency of the infarct-related artery at index angiography and a significantly lower chance of all-cause death, stroke, recurrent myocardial infarction (MI)...
  • BETTER-BP, GOFRESH & Healthy Family: Fresh Ideas For BP Control
    With high blood pressure (BP) continuing to be a global challenge, effective management must remain a global priority. The results from three late-breaking studies presented at AHA 2025 are shedding light on diverse behavioral, nutritional and family-centered strategies that may help inform larger-scale models that can be implemented worldwide.
  • DECAF: Does One Cup of Coffee a Day Keep AFib Away?
    Patients with atrial fibrillation (AFib) who drank an average of one cup of coffee a day following successful cardioversion had fewer recurrences of AFib or atrial flutter compared with those who abstained from coffee, based on findings from the DECAF trial presented at AHA 2025 and simultaneously published in JAMA.